Stada And Xbrane Receive MHRA Nod For Ranibizumab
Ximluci Biosimilar Rival To Lucentis Will Be Launched ‘During 2023’
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.
